Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/2045893217703369 http://scihub22266oqcxt.onion/10.1177/2045893217703369 C5467934!5467934!28597771     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 251.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Pulm+Circ 2017 ; 7 (2): 551-4 Nephropedia Template TP {{tp|p=28597771|t=2017. First-in-child use of the oral selective prostacyclin IP receptor agonist selexipag in pulmonary arterial hypertension |pdf=|usr=}}{{28597771}} gab.com Text First-in-child use of the oral selective prostacyclin IP receptor agonist selexipag in pulmonary arterial hypertension JO: Pulm Circ http://www.kidney.de/pget.php?&tw=1&pmid=28597771 #FOAvip Pulmonary arterial hypertension (PAH) is a complex disease with a poor prognosis. Selexipag is a selective prostacyclin receptor agonist with vasodilatory, anti-proliferative, anti-inflammatory, and pro-angiogenic properties. However, no clinical data on its therapeutic use in children with PAH are currently available. Here, we report the case of a 12-year-old girl who presented in World Health Organization (WHO) functional class III and right ventricular (RV) failure with recurrent syncope, dizziness, and progressive fatigue for two years. Cardiac catheterization revealed severe precapillary PAH: mean right atrial pressure (RAP)?=?10?13?mmHg, right ventricular end-diastolic pressure (RVEDP)?=?13?mmHg, left ventricular end-diastolic pressure (LVEDP)?=?7?mmHg, mean pulmonary arterial pressure (PAP)?=?81?mmHg, and mean aorta ascendens pressure?=?89?mmHg. The pulmonary vascular resistance index (PVRi) was 25.2?WU?×?m2. An oral combination therapy was started with a phosphodiesterase type 5 inhibitor (sildenafil 3?×?20?mg) and an endothelin-1 receptor antagonist (bosentan 2?×?62.5?mg). No significant clinical/hemodynamic improvement was seen after nine months of dual therapy, so that the patient was transferred to our institution. We agreed upon the off-label add-on use of oral selexipag. Within ten days, we up-titrated selexipag to a final (max. adult) dose of 1600?mcg twice daily. After six months, the patient had: (1) decrease in PVR index, pulmonary artery acceleration time, RAP, RVEDP, right atrial/RV size; (2) re-gain of vasoreactivity; and (3) improvement of cardiac index, 6-minute walking distance, functional class, body weight, and CAMPHOR score. Our encouraging results suggest the consideration of off-label use of oral selexipag in children with severe PAH, preferably in a protocol-driven prospective study. Twit Text FOAVip First-in-child use of the oral selective prostacyclin IP receptor agonist selexipag in pulmonary arterial hypertension ????Pulm Circ http://www.kidney.de/pget.php?&tw=1&pmid=28597771 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28597771 #FOAvip English Wikipedia <ref>{{Cite pmid|28597771}}</ref> First-in-child use of the oral selective prostacyclin IP receptor agonist selexipag in pulmonary arterial hypertension #MMPMID28597771 Geerdink LM; Bertram H; Hansmann G Pulm Circ 2017[Jun]; 7 (2): 551-4 PMID28597771show ga Pulmonary arterial hypertension (PAH) is a complex disease with a poor prognosis. Selexipag is a selective prostacyclin receptor agonist with vasodilatory, anti-proliferative, anti-inflammatory, and pro-angiogenic properties. However, no clinical data on its therapeutic use in children with PAH are currently available. Here, we report the case of a 12-year-old girl who presented in World Health Organization (WHO) functional class III and right ventricular (RV) failure with recurrent syncope, dizziness, and progressive fatigue for two years. Cardiac catheterization revealed severe precapillary PAH: mean right atrial pressure (RAP)?=?10?13?mmHg, right ventricular end-diastolic pressure (RVEDP)?=?13?mmHg, left ventricular end-diastolic pressure (LVEDP)?=?7?mmHg, mean pulmonary arterial pressure (PAP)?=?81?mmHg, and mean aorta ascendens pressure?=?89?mmHg. The pulmonary vascular resistance index (PVRi) was 25.2?WU?×?m2. An oral combination therapy was started with a phosphodiesterase type 5 inhibitor (sildenafil 3?×?20?mg) and an endothelin-1 receptor antagonist (bosentan 2?×?62.5?mg). No significant clinical/hemodynamic improvement was seen after nine months of dual therapy, so that the patient was transferred to our institution. We agreed upon the off-label add-on use of oral selexipag. Within ten days, we up-titrated selexipag to a final (max. adult) dose of 1600?mcg twice daily. After six months, the patient had: (1) decrease in PVR index, pulmonary artery acceleration time, RAP, RVEDP, right atrial/RV size; (2) re-gain of vasoreactivity; and (3) improvement of cardiac index, 6-minute walking distance, functional class, body weight, and CAMPHOR score. Our encouraging results suggest the consideration of off-label use of oral selexipag in children with severe PAH, preferably in a protocol-driven prospective study. äFirst-in-child use of the oral selective prostacyclin IP receptor agon(epmc).pdf DeepDyve Pubget Overpricing